Patents by Inventor Assaf Lask

Assaf Lask has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230398214
    Abstract: Methods of generating an isolated population of non-graft versus host disease (GVHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation, are disclosed. Cells generated by the methods, pharmaceutical compositions and methods of treatment are also disclosed.
    Type: Application
    Filed: August 6, 2020
    Publication date: December 14, 2023
    Applicants: Yeda Research and Development Co. Ltd., Board of Regents, The University of Texas System
    Inventors: Yair REISNER, Esther BACHAR-LUSTIG, Assaf LASK, Noga OR-GEVA, Rotem GIDRON BUDOVSKY, Rakefet SIDLIK MUSKATEL
  • Publication number: 20230383254
    Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.
    Type: Application
    Filed: August 10, 2023
    Publication date: November 30, 2023
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair REISNER, Noga OR-GEVA, Rotem GIDRON BUDOVSKY, Esther BACHAR-LUSTIG, Assaf LASK, Sivan KAGAN
  • Publication number: 20230321235
    Abstract: A method of generating a population of genetically modified veto cells is disclosed. The method comprising: (a) providing a population of cells comprising T cells, the T cells comprising at least 40% memory CD8+ T cells; (b) culturing the population of cells comprising T cells with an antigen or antigens under conditions which allow enrichment of tolerance-inducing antigen-specific cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being depleted of graft versus host (GVH) reactivity; and (c) transducing the cells with a polynucleotide encoding a heterologous cell surface receptor comprising a T cell receptor signaling module, thereby generating the population of genetically modified veto cells.
    Type: Application
    Filed: August 11, 2021
    Publication date: October 12, 2023
    Applicants: Yeda Research and Development Co. Ltd., Ichilov Tech Ltd.
    Inventors: Yair REISNER, Anat GLOBERSON LEVIN, Esther BACHAR-LUSTIG, Assaf LASK, Bar NATHANSOHN-LEVI, Tova WAKS, Galit HORN, Zelig ESHHAR
  • Patent number: 11773372
    Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: October 3, 2023
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Noga Or-Geva, Rotem Gidron Budovsky, Esther Bachar-Lustig, Assaf Lask, Sivan Kagan
  • Publication number: 20230024587
    Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.
    Type: Application
    Filed: May 3, 2022
    Publication date: January 26, 2023
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair REISNER, Yaki EIDELSTEIN, Eran OPHIR, Assaf LASK, Ran AFIK, Noga OR-GEVA, Esther BACHAR-LUSTIG
  • Patent number: 11324777
    Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: May 10, 2022
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Yaki Eidelstein, Eran Ophir, Assaf Lask, Ran Afik, Noga Or-Geva, Esther Bachar-Lustig
  • Publication number: 20210214687
    Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.
    Type: Application
    Filed: March 25, 2021
    Publication date: July 15, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair REISNER, Noga OR-GEVA, Rotem GIDRON BUDOVSKY, Esther BACHAR-LUSTIG, Assaf LASK, Sivan KAGAN
  • Patent number: 10961504
    Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: March 30, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Noga Or-Geva, Rotem Gidron Budovsky, Esther Bachar-Lustig, Assaf Lask, Sivan Kagan
  • Publication number: 20190316087
    Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 17, 2019
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair REISNER, Noga OR-GEVA, Rotem GIDRON BUDOVSKY, Esther BACHAR-LUSTIG, Assaf LASK, Sivan KAGAN
  • Publication number: 20180193384
    Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.
    Type: Application
    Filed: November 29, 2017
    Publication date: July 12, 2018
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair REISNER, Yaki EIDELSTEIN, Eran OPHIR, Assaf LASK, Ran AFIK, Noga OR-GEVA, Esther BACHAR-LUSTIG
  • Publication number: 20160354410
    Abstract: A method of treating a disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting a non-syngeneic cell or tissue graft to the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of cells comprising non-graft versus host (GVHD) inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, and further wherein the cells are either: (i) non-syngeneic with both the subject and the graft; or (ii) non-syngeneic with the graft and syngeneic with the subject, thereby treating the subject.
    Type: Application
    Filed: August 22, 2016
    Publication date: December 8, 2016
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair REISNER, Assaf LASK, Eran OPHIR, Noga OR-GEVA, Adva COHEN, Ran AFIK, Esther BACHAR-LUSTIG, Yaki EIDELSTEIN
  • Patent number: 9421228
    Abstract: A method of treating a disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting a non-syngeneic cell or tissue graft to the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of cells comprising non-graft versus host (GVHD) inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, and further wherein the cells are either: (i) non-syngeneic with both the subject and the graft; or (ii) non-syngeneic with the graft and syngeneic with the subject, thereby treating the subject.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: August 23, 2016
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Assaf Lask, Eran Ophir, Noga Or-Geva, Adva Cohen, Ran Afik, Esther Bachar-Lustig, Yaki Eidelstein
  • Publication number: 20140212398
    Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.
    Type: Application
    Filed: September 6, 2012
    Publication date: July 31, 2014
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Yaki Eidelstein, Eran Ophir, Assaf Lask, Ran Afik, Noga Or-Geva, Esther Bachar-Lustig
  • Publication number: 20130171108
    Abstract: A method of treating a disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting a non-syngeneic cell or tissue graft to the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of cells comprising non-graft versus host (GVHD) inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, and further wherein the cells are either: (i) non-syngeneic with both the subject and the graft; or (ii) non-syngeneic with the graft and syngeneic with the subject, thereby treating the subject.
    Type: Application
    Filed: September 8, 2011
    Publication date: July 4, 2013
    Applicant: Yeda Research and Development Co., Ltd.
    Inventors: Yair Reisner, Assaf Lask, Eran Ophir, Noga Or-Geva, Adva Cohen, Ran Afik, Esther Bachar-Lustig, Yaki Eidelstein